{"filings":[{"id":1223916,"accession_number":"0001104659-26-076845","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2026-06-23T20:52:19+00:00","items":["5.07"],"status":"ready","headline":"Orchestra BioMed shareholders elect directors, approve ESPP and auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors: Hochman (39.7M for), Sherman (39.5M), Fain (37.8M); no contested.","Ratified Ernst & Young as auditor for FY 2026: 49.0M for, 13,692 against.","Approved 2026 Employee Stock Purchase Plan: 39.6M for, 150,243 against.","Advisory say-on-pay approved: 38.0M for, 1.8M against, 67,523 abstain.","Advisory vote on say-on-pay frequency: 39.0M preferred 1 year; company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108941,"accession_number":"0001104659-26-015315","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.","President/COO Mark Sherman base salary raised 10%; target bonus increased from 80% to 90% of base.","2026 bonus plan ties to clinical trial enrollment milestones for BACKBEAT and Virtue SAB studies.","RSU awards now vest 25% at 18, 24, 30, and 36 months; prior schedule changed.","CFO Andrew Taylor's bonus can be adjusted -45% to +0% based on individual performance objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108940,"accession_number":"0001104659-26-002752","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.","Remaining up to $10M from future revenue earnouts based on milestone achievement.","Vivasure's PerQseal Elite received CE Mark and filed PMA with FDA; 0% major complications at 30 days.","Haemonetics closed acquisition on January 9, 2026; OBIO was strategic holder since formation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125396,"accession_number":"0001104659-25-110907","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed secures $147M+ funding; BACKBEAT enrollment mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over $147M in strategic financing since August 2025; Ligand commits additional $31.6M for royalty interest.","Terumo pays $30M for ROFR on Virtue SAB global coronary market; total Terumo payments $65M.","BACKBEAT hypertension pivotal trial (N=500) enrollment completion expected mid-2026.","Virtue Trial (coronary ISR) IDE approved, N=740, initiated in 2H 2025.","Cash runway expected through Q4 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125395,"accession_number":"0001104659-25-104016","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed posts investor presentation; no new material facts disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor slide deck under Item 7.01; content not detailed in the 8-K text.","Presentation dated October 2025; available on company IR website.","No specific financial or operational updates contained in the filing text.","Ticker OBIO; company is an emerging growth company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125394,"accession_number":"0001104659-25-102862","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed restructures Terumo deal: $30M total, retains Virtue SAB rights, starts pivotal trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terumo pays $10M for ROFR on Virtue SAB coronary rights globally; $20M equity investment via Series A convertible preferred at $100/share.","Prior $30M non-refundable payment and $5M common stock investment unchanged; Terumo total commitment now $65M.","Orchestra BioMed retains full rights for below-the-knee peripheral artery disease and other non-coronary indications.","First patients enrolled in Virtue Trial (U.S. pivotal IDE for coronary ISR, 740 patients, enrollment mid-2027).","Virtue SAB has FDA Breakthrough Device Designation; pilot data showed 12-month TLF 2.8% and zero TLR from 12–36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142129,"accession_number":"0001104659-25-073641","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed raises ~$56M via public offering and private placement; grants warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 9,413,637 shares at $2.75/sh + pre-funded warrants for 5,136,363 shares at $2.7499; gross $40M.","Underwriters granted 30-day option for up to 2,182,500 additional shares at same price.","Concurrent private placement: 5,895,608 shares to Ligand and Medtronic affiliate for ~$16.2M.","Ligand receives warrant for up to 2M shares at $3.67, issued upon closing of placement.","Proceeds to fund AVIM therapy BACKBEAT study, Virtue SAB program/trial, and general corporate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142128,"accession_number":"0001104659-25-072678","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed secures up to $67M in financing from Ligand & Medtronic; cash ~$33.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ligand pays $35M for tiered revenue rights on BACKBEAT & Virtue SAB products; also buys $5M stock and gets 2M-share warrant.","Medtronic provides $20M convertible loan at 11% interest, plus up to $12M equity purchase in subsequent offering.","Hercules loan amended: amortization delayed, borrowing capacity increased by $15M; warrant terms modified.","Preliminary June 30 cash $33.9M; Terumo mediation expected to complete in Q3 2025.","BACKBEAT study enrollment now expected mid-2026; FDA-approved amendments to expand patient eligibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160103,"accession_number":"0001104659-25-062105","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Orchestra BioMed stockholders elect directors, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors Chris Cleary, Pamela Connealy, David Pacitti elected to serve until 2028.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec. 31, 2025.","28,177,159 of 38,312,512 eligible shares represented at the June 24, 2025 annual meeting.","Each director received over 24.5 million votes for and ~3.6 million broker non-votes.","Auditor ratification passed with 28,140,709 votes for, 34,087 against, 2,363 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160102,"accession_number":"0001104659-25-040763","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed gets FDA Breakthrough Device Designation for AVIM therapy and IDE approval for Virtue SAB trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Device Designation for AVIM therapy; covers >7.7M U.S. hypertension patients.","AVIM therapy BDD may expedite FDA review and support higher reimbursement (NTAP/TPT).","FDA approved IDE amendment for Virtue SAB randomized trial vs AGENT paclitaxel DCB for coronary ISR.","Virtue Trial plans 740 patients across 75 U.S. centers; targeting H2 2025 start.","Virtue SAB pilot showed 12-month TLF 2.8% and 6-month late lumen loss 0.12mm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178425,"accession_number":"0001104659-25-019500","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed files 8-K furnishing Q1 2025 investor slide presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed a slide presentation used at investor conferences as Exhibit 99.1.","Presentation posted on company website under Investor Relations section.","No specific financial or operational updates extractable from filing text; presentation content not readable due to encoding.","Filing is a routine Regulation FD disclosure; no new material news identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178424,"accession_number":"0001104659-25-016950","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Orchestra BioMed approves new cash bonus plan and equity policies for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Hochman and President Sherman eligible for 80% base salary cash bonus; CFO Taylor eligible for 50%.","2025 goals include BACKBEAT enrollment, Virtue Sirolimus program milestones, pipeline/partnerships, financial objectives.","Stretch goals can boost bonus up to 60%; CFO bonus further adjustable up to 45% or zero on individual performance.","VP+ officers may elect equity as 100% options, 100% RSUs, or 50/50; RSUs vest over 3 years starting at 24 months.","Section 16 officers' RSU tax liabilities satisfied by share withholding, not market sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178423,"accession_number":"0001104659-25-009393","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orchestra BioMed appoints former Medtronic SVP Chris Cleary to board; Dr. Eric Rose resigns as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Cleary appointed as Class II independent director effective Jan 30, 2025; board expanded to nine.","Cleary was Medtronic SVP of Corporate Development, led $50B Covidien acquisition and $6B asset sale to Cardinal Health.","Cleary previously helped shape Orchestra BioMed's AVIM therapy strategic collaboration with Medtronic.","Eric Rose resigned as director Feb 3, 2025; remains as Emeritus Board Member and Strategic Advisor.","Board expected to decrease to eight members following Rose resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211371,"accession_number":"0001104659-24-088431","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Orchestra BioMed enters $100M ATM sales agreement with TD Cowen, terminates Jefferies facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New sales agreement with TD Securities (USA) LLC for up to $100M of common stock in at-the-market offerings.","Prior $100M ATM agreement with Jefferies LLC terminated; $15.5M had been sold under it, $84.5M remained unused.","Termination intended to eliminate restrictions on Jefferies publishing research reports on the company.","Offering is under existing shelf registration statement (filed May 2024); no obligation to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211370,"accession_number":"0001104659-24-083973","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Orchestra BioMed appoints John Mack to board; former Medtronic Cardiac Surgery President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Mack appointed as Class I director effective July 29, 2024; term expires at 2027 annual meeting.","Mack previously served as Medtronic's President of Cardiac Surgery and led business development for its $3.2B coronary/structural heart business.","Appointed to Audit Committee; Board size increased from 7 to 8 directors.","No family relationships or transactions requiring disclosure under Item 404(a).","Mack will receive standard non-employee director compensation per existing policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229992,"accession_number":"0001104659-24-073435","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Orchestra BioMed stockholders elect directors and ratify auditor at 2024 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["28.6M shares voted (80% of 35.8M eligible); both Class I directors elected.","Eric A. Rose, M.D. received 22.5M for, 2.2M withheld; Jason Aryeh received 24.0M for, 0.6M withheld.","Ratification of Ernst & Young as independent auditor approved with 28.6M for, 25.4K against, 2.4K abstentions.","No other proposals were voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229991,"accession_number":"0001104659-24-070204","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed holds R&D Day on AVIM Therapy; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["R&D Day held June 11, 2024; presentation covers AVIM Therapy platform.","Presentation used at investor conferences; no new specific metrics or outcomes provided.","No changes to outlook, pipeline milestones, or capital structure announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248437,"accession_number":"0001104659-24-041173","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Orchestra BioMed sets first Annual Meeting for June 20, 2024; record date April 26","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for June 20, 2024; location and time in upcoming proxy statement.","Record date for voting eligibility set as April 26, 2024.","Deadline for Rule 14a-8 shareholder proposals is April 8, 2024; for director nominations same date under bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248436,"accession_number":"0001104659-24-031605","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed files corporate presentation; no material updates provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an investor slide presentation used at Q1 2024 conferences.","Presentation contains only standard forward-looking statement disclaimers.","No earnings, guidance, or material business events disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265929,"accession_number":"0001104659-23-121331","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Orchestra BioMed amends registration rights agreement, delaying S-1 amendment and effectiveness deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Obligation to amend S-1 deferred to earlier of April 1, 2024 or 15 business days after filing 2023 10-K.","Effectiveness deadline pushed to 90 days after filing first amendment or 10 business days after SEC clearance.","Amendment involves Medtronic affiliate Covidien Group S.à.r.l. and other investors.","Replaces the prior amended registration rights agreement from January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265928,"accession_number":"0001104659-23-117492","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed files 8-K furnishing Q4 2023 investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company furnished investor presentation as Exhibit 99.1 for use at conferences.","Presentation is furnished under Regulation FD and not deemed filed for liability purposes.","CEO David P. Hochman signed the report on November 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265927,"accession_number":"0001104659-23-108359","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed postpones Virtue SAB pivotal study to 2024 amid Terumo negotiations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed registration statement for resale of shares/warrants; not seeking additional capital.","Negotiating with Terumo to restructure milestone payments and modify distribution agreement.","Virtue ISR-US pivotal study initiation postponed to 2024 due to ongoing negotiations.","If negotiations not satisfactory, clinical/commercial plans for Virtue SAB may be further affected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283151,"accession_number":"0001104659-23-101763","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants IDE approval for Orchestra BioMed's BACKBEAT pivotal study of BackBeat CNT in hypertensive pacemaker patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IDE for global pivotal BACKBEAT study evaluating AVIM therapy (BackBeat CNT) for hypertension in pacemaker patients.","Study to randomize ~500 patients 1:1, primary endpoint: change in mean 24-hour ambulatory systolic BP at 3 months.","Orchestra BioMed collaborating with Medtronic; Medtronic has exclusive global commercialization rights if approved.","Supported by MODERATO II pilot study: net reduction of 8.1 mmHg in 24-hour aSBP and 12.3 mmHg in oSBP at 6 months.","Enrollment expected to start before end of 2023; study designed to support future regulatory review and potential approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283149,"accession_number":"0001104659-23-080462","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K/A","filed_at":"2023-07-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed files 8-K/A to correct prior investor presentation","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Amendment corrects the investor presentation originally filed on July 12, 2023; revised Exhibit 99.1 supersedes prior version.","No other changes to the original 8-K; the correction is not specified in the filing.","Revised presentation is used at investor conferences and posted on the company's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283150,"accession_number":"0001104659-23-080208","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed furnishes routine investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a slide presentation (Ex 99.1) used at investor conferences and posted on its website.","Presentation covers pipeline and business overview, typical for corporate update, no specific financial results or guidance changes.","No new material events, transactions, or regulatory updates announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302548,"accession_number":"0001104659-23-069440","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed appoints Andrew Taylor as CFO, Bill Little as EVP Corp Dev","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Kaswan stepped down as CFO effective June 6, 2023; will consult at $36,180/month for up to 6 months.","Andrew Taylor appointed CFO; formerly CFO of Motus GI (MOTS), base salary $395,000, target bonus 50% of salary, initial equity grant of up to 278,502 RSUs or 417,544 options.","Bill Little appointed EVP of Corporate Development and Strategy; previously COO of Neovasc until its acquisition by Shockwave Medical.","Kaswan's consulting agreement includes $108,540 lump sum and additional three months' service vesting for equity.","Little to focus on strategic collaborations; partnerships with Medtronic and Terumo continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302547,"accession_number":"0001104659-23-069162","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Orchestra BioMed reports positive clinical data; plans pivotal trials H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BackBeat CNT showed 8.1 mmHg net reduction in 24-hour aSBP at 6 months and 17.5 mmHg oSBP reduction at 2 years.","Virtue SAB in coronary ISR: 0.12 mm late lumen loss at 6 months, 2.8% target lesion failure at 1 year.","Pivotal trials for BackBeat CNT and Virtue SAB intend to start in H2 2023.","Medtronic collaboration: double-digit revenue share and $50M equity investment; Terumo: 10-15% royalty and $30M upfront.","Target markets: >$10B (BackBeat CNT) and >$3B (Virtue SAB); strong balance sheet with committed investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322201,"accession_number":"0001213900-23-022800","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K/A","filed_at":"2023-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Orchestra BioMed reports 2022 net loss of $33.6M; revenue up to $3.5M from negative prior year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss was $33.6M for 2022 vs $23.0M in 2021; operating expenses rose to $36.2M.","Revenue of $3.5M included $2.9M partnership revenue; product revenue flat at $0.7M.","Cash and marketable securities totaled $83.7M at Dec 31, 2022, up from $9.9M; funded by Series D preferred stock.","Accumulated deficit reached $199.7M; management expects continued losses but has sufficient liquidity post-merger.","Business combination with HSAC2 (SPAC) closed Jan 2023; audited financials now filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322203,"accession_number":"0001213900-23-019415","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Orchestra BioMed confirms SVB exposure less than 1% of total cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Less than 1% of total cash, cash equivalents and marketable securities held at Silicon Valley Bank.","Company states exposure to SVB is de minimis and not material.","Filed investor slide presentation for Q1 2023; no material new disclosures beyond SVB update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322202,"accession_number":"0001213900-23-006448","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["1.01","2.01","9.01","5.02","3.02","4.01","3.03","8.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Orchestra BioMed completes business combination, 20.2M shares issued, earnout up to 8M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Jan 26, 2023; each Orchestra share exchanged for 0.465 HSAC2 share; 20.2M new shares issued to Orchestra stockholders.","Earnout: up to 8M additional shares contingent on $15 and $20 VWAP milestones; 91% of Orchestra stockholders elected to participate.","RTW and Medtronic provided $20M forward purchase; RTW backstop purchased 1.81M shares at $10 to ensure $60M minimum cash.","Sponsor forfeited 750K warrants; 750K new warrants issued to employees with 24-36 month vesting.","Lock-up: 12 months for initial shareholders and RTW; 6 months for other holders; registration rights filed within 120 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322200,"accession_number":"0001213900-23-005022","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Health Sciences Acquisitions 2 shareholders approve merger with Orchestra BioMed; closing expected Jan 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All 9 proposals approved at Jan 24 EGM, including Merger Agreement, Domestication, and Equity Incentive Plan.","Business Combination with Orchestra BioMed to close in January 2023, subject to remaining conditions.","Directors elected for New Orchestra: Eric Rose, Jason Aryeh, Pamela Connealy, Geoffrey Smith, David Hochman, Darren Sherman, Eric Fain.","Vote results: 9.44M for (96.5% of voting) on Business Combination Proposal; quorum of 87.2% achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322199,"accession_number":"0001213900-23-004618","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Health Sciences Acquisitions Corp 2 receives Nasdaq delisting notice for failing to hold annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 19, 2023 for failure to hold annual meeting within 12 months after FY2021 end (Dec 31, 2021).","Has until March 5, 2023 to submit compliance plan; if accepted, deadline extended to June 29, 2023.","Company does not intend to submit plan; expects to resolve via business combination with Orchestra BioMed at Jan 24, 2023 meeting.","If business combination approved, combined company treated as newly listed; annual meeting due by Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322198,"accession_number":"0001213900-23-004510","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HSAC2 receives redemption requests for 1.6M shares ahead of Jan 24 merger vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Jan 23, 2023, 1,597,888 ordinary shares tendered for redemption by shareholders.","Extraordinary general meeting scheduled for Jan 24, 2023 to vote on business combination with Orchestra BioMed.","Redemption requests relate to pro rata portion of trust account from HSAC2's IPO; exact trust value not disclosed.","Shareholders may still redeem shares up to the vote; final redemption count may change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340261,"accession_number":"0001213900-22-081777","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"Health Sciences Acquisitions Corp 2 extends business combination deadline to February 6, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company's directors elected to extend deadline to February 6, 2023, from prior extended date of November 6, 2022.","Extension approved by shareholders in July 2022; allows up to three monthly extensions without another vote.","If no business combination by Feb 6, 2023, company will cease operations, redeem shares, and liquidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340260,"accession_number":"0001213900-22-073189","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"Health Sciences Acquisitions Corp 2 extends SPAC deadline to Jan 6, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board elected to extend business combination deadline from Nov 6, 2022 to Jan 6, 2023.","Extension is the first of up to three monthly extensions allowed by shareholder-approved amendment.","If no business combination by Jan 6, 2023, Company must redeem shares and dissolve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340259,"accession_number":"0001213900-22-067738","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"HSAQ board elects to extend business combination deadline to December 6, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension adds one month to the prior deadline of November 6, 2022.","Company may extend monthly up to three times, now until December 6, 2022.","Shareholders approved the extension mechanism in July 2022.","No business combination consummated yet; SPAC continues searching for target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340258,"accession_number":"0001213900-22-065563","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"HSAC2 amends backstop and forward purchase agreements with RTW Funds for Orchestra deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Per-share purchase price under both agreements capped at the shareholder redemption price (not exceeding $10.00).","RTW Funds agree not to vote shares purchased under these agreements in favor of the business combination.","RTW Funds waive redemption rights for those shares in connection with the vote to approve the combination.","Amendments executed on October 21, 2022, modifying the July 4, 2022 agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357531,"accession_number":"0001213900-22-041877","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve extension of business combination deadline to Nov 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension Proposal approved: 15,084,246 for, 1,365,812 against, 0 abstain.","Deadline extended from Aug 6, 2022 to Nov 6, 2022, with option for monthly extensions to Feb 6, 2023.","Proxies received for 80.4% of 20,450,000 outstanding shares, quorum present.","Adjournment Proposal not needed due to sufficient votes for Extension Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357530,"accession_number":"0001213900-22-041497","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HSAC2 gets redemption requests for 9.2M shares; RTW Funds buys 1M shares at $10.01 to back Orchestra BioMed deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of July 22, 2022, shareholders requested redemption of 9,237,883 HSAC2 ordinary shares ahead of July 26 vote on extension to Nov 6, 2022.","RTW Funds (manager affiliate) purchased 1,000,000 HSAC2 shares at $10.01/share from an accredited investor in a private transaction.","Purchase fulfills RTW's obligations under Forward Purchase Agreement with HSAC2 and Orchestra BioMed, and prevents redemption of those shares to retain trust funds.","The action increases likelihood that the proposed business combination with Orchestra BioMed ultimately closes.","The extension proposal would allow additional monthly extensions up to February 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357529,"accession_number":"0001140361-22-024892","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"HSAC2 (HSAQ) enters SPAC merger with Orchestra BioMed; $20M forward purchase agreements, $60M cash condition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Orchestra stockholders receive 0.465 HSAC2 shares per share; earnout up to 8M additional shares at $15/$20 VWAP milestones.","RTW Funds and Medtronic affiliate each commit $10M in forward purchases; RTW also backstops to meet $60M minimum cash condition.","Minimum $60M cash at closing required; sponsor forfeits 1M shares and 750K warrants subject to earnout and lock-up conditions.","Post-closing company renamed Orchestra BioMed Holdings; board will consist of existing Orchestra directors.","Outside closing date February 6, 2023; deal requires shareholder and regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394483,"accession_number":"0001213900-22-006431","cik":1814114,"company_name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Health Sciences Acquisitions 2 restates financial statements due to equity classification error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concludes all ordinary shares should be classified as temporary equity, not permanent.","Restatement covers six prior filings from August 2020 through September 2021, including IPO balance sheet.","No impact on cash position or trust account; earnings per share presentation also revised.","Material weakness in internal control over financial reporting identified; disclosure controls ineffective.","Company plans to file amended 10-K, 10-Q, and 8-K to correct the affected periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239822264.33544305,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}